SYNAPTOGENIX
Synaptogenix is a clinical-stage biotech company leveraging Bryostatin-1 and its analogs to discover and develop targeted therapeutics for neurodegenerative diseases and developmental disorders. The company has targeted Bryostatin-1 due to its high potential and multi-modal efficacy: through protein kinase C (PKCϵ) activation, Bryostatin-1 stimulates synaptic growth factors, amyloid-β degrading enzymes, as well as prevents Tau transformation into neurofibrillary tangles.
SYNAPTOGENIX
Industry:
Biopharma Biotechnology Pharmaceutical
Founded:
2012-01-01
Status:
Active
Contact:
973-242-0005
Total Funding:
41.5 M USD
Technology used in webpage:
Content Delivery Network Global Site Tag Sitelinks Search Box Yoast WordPress SEO Plugin Yoast Plugins Yoast SEO Premium Pound Sterling Japanese Yen Digital Ocean Global Privacy Control
Similar Organizations
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
Arcellx
Arcellx is a clinical-stage biotechnology company that provides patients with immune cell therapies.
AZTherapies
AZTherapies is a clinical stage biotech company developing breakthrough treatments for neuroinflammation-related diseases.
Cytokinetics
Cytokinetics is a biopharmaceutical company developing therapies for debilitating diseases.
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Eidos Therapeutics
Eidos Therapeutics is a clinical-stage biotech company developing novel, genetically targeted therapies to improve the lives of patients.
PhaseBio Pharmaceuticals
PhaseBio is a clinical-stage biopharmaceutical company that develops drugs for cardiovascular diseases, endocrine, and metabolic disorders.
Reata Pharmaceuticals
Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases.
Sirnaomics
Sirnaomics is a biopharmaceutical company developing therapeutics for critical human diseases by using RNA interference technology.
Current Employees Featured
Robert Weinstein Chief Financial Officer @ Synaptogenix
Chief Financial Officer
2013-06-01
Daniel Alkon President & Chief Scientific Officer @ Synaptogenix
President & Chief Scientific Officer
Alan Tuchman Chief Executive Officer @ Synaptogenix
Chief Executive Officer
2020-01-01
Founder
Stock Details
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2023-11-02 | CannaSoul Analytics | Synaptogenix investment in Venture Round - CannaSoul Analytics | 4 M USD |
More informations about "Synaptogenix"
IR - Synaptogenix
Synaptogenix, Inc. Quarter Ended September 30, 2020: November 2, 2020: DEFM14a: Definitive Proxy Statement for Annual and Special Shareholder Meeting: October 15, 2020: 425: …See details»
Synaptogenix - Crunchbase Investor Profile
Synaptogenix is a clinical-stage biotech company leveraging Bryostatin-1 and its analogs to discover and develop targeted therapeutics for neurodegenerative diseases and developmental disorders. The company has targeted Bryostatin …See details»
Investor Relations - Synaptogenix
Synaptogenix, Inc. seeks to enhance shareholder value not only through exceptional business performance and practices, but also through responsible and effective communication with its shareholders. The latest company …See details»
Synaptogenix, Inc. (SNPX) Company Profile & Overview - Stock …
3 days ago The U.S. Food and Drug Administration has granted Orphan Drug Designation to Synaptogenix for Bryostatin-1 as a treatment for Fragile X syndrome. The company was …See details»
Synaptogenix, Inc. (SNPX) Company Profile & Facts - Yahoo Finance
See the company profile for Synaptogenix, Inc. (SNPX) including business summary, industry/sector information, number of employees, business summary, corporate governance, …See details»
Pioneers of Restorative Therapeutics - Synaptogenix
Synaptogenix is a clinical-stage biopharmaceutical company discovering restorative, novel therapeutics for patients with life-altering neurodegenerative diseases and developmental …See details»
Synaptogenix - Org Chart, Teams, Culture & Jobs - The Org
View Synaptogenix's up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more. This is an unverified company page.See details»
Synaptogenix - Funding, Financials, Valuation & Investors
Synaptogenix is a clinical-stage biopharmaceutical company that develops novel therapies for neurodegenerative diseases. Search Crunchbase. Start Free Trial . ... How much funding has …See details»
Corporate Governance - Synaptogenix
Synaptogenix, Inc. 1185 Avenue of the Americas 3rd Floor New York, NY 10036. IR Contact T: 800-811-5591 ir@synaptogen.com. Corporate Governance. by rimotevst | Dec 3, 2019. Audit …See details»
Synaptogenix, Inc. - VentureRadar
Synaptogenix is a clinical-stage biotech company leveraging Bryostatin-1 and its analogues to discover and develop targeted, novel regenerative therapeutics for neurodegenerative …See details»
Synaptogenix Company Profile 2024: Stock Performance
Synaptogenix General Information Description. Synaptogenix Inc is a biopharmaceutical company with product candidates in pre-clinical and clinical development. It is principally focused on …See details»
Synaptogenix - Investments, Portfolio & Company Exits
Synaptogenix is a clinical-stage biopharmaceutical company that develops novel therapies for neurodegenerative diseases.See details»
Synaptogenix, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
About Synaptogenix Synaptogenix is a clinical-stage biopharmaceutical company that has historically worked to develop novel therapies for neurodegenerative diseases. Synaptogenix …See details»
Synaptogenix Company Profile - Office Locations, Competitors
Oct 29, 2024 Synaptogenix (formerly known as Neurotrope Bioscience) is a biopharmaceutical company that specializes in therapies for neurodegenerative diseases. It develops a product …See details»
Synaptogenix Board of Directors Forms Special Committee to …
NEW YORK, Dec. 20, 2024 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for …See details»
Home v1 - Synaptogenix
Investor Call December 14, 2020 Synaptogenix is discovering restorative therapeutics for patients with life-altering neurodegenerative diseases and developmental disorders. WHO WE ARE …See details»
Neurotrope completes formation of new company Synaptogenix
Dec 14, 2020 Neurotrope announced the completion of an independent spin-off of neurotrope bioscience, which has now been renamed as Synaptogenix, trading under the symbol SNPX. …See details»
Synaptogenix Board of Directors Forms Special Committee to …
Dec 23, 2024 Synaptogenix, Inc. is a clinical-stage biopharmaceutical company developing therapeutics for neurodegenerative disorders. The Company is principally focused on …See details»
Synaptogenix Restructures Leadership Amid Strategic Refocus
Dec 20, 2024 Synaptogenix is a clinical-stage biopharmaceutical company focused on developing novel therapies for neurodegenerative diseases. Its lead therapeutic candidate, …See details»
Synaptogenix Abstract Highlighting Bryostatin-1 Benefits in Severe ...
Jul 13, 2023 Synaptogenix Abstract Highlighting Bryostatin-1 Benefits in Severe Alzheimer's Disease Accepted for Presentation at 11th International Brain Research Organization World …See details»